AJOVY is available in an autoinjector. Learn more

You had searched for:

There were no results matching the query.

You can also browse the topics below to find what you are looking for.

Patient Profiles


Maura
Anna

Need help answering a question?

Support Services

  1. Download the Prescription and Service Request Form (PSRF)
  2. Fax the completed form to Shared Solutions® at 1-844-257-6127

Patients can call 1-800-887-8100, Monday–Friday, 8 am–6 pm CT.

More migraine-free days with as few as 4 injection days a year and results seen as early as one week1,2

Select the data:

Primary endpoint + long-term extension
Response rates

With AJOVY, patients experienced significantly more migraine-free days vs placebo with results seen as early as 1 week1,2

+ Long-Term Extension

See STUDY design

CHRONIC MIGRAINE

Line chart describing clinical trial data of the pivotal HALO Chronic Migraine trial from months 1 to 3 and Long-Term Extension study from months 3 to 12.

Consider limitations of Long-Term Extension study design when interpreting efficacy results.

Patients randomized to quarterly dosing had a mean baseline of 13.2 headache days of at least moderate severity per month and experienced, on average1:

4.7 fewer headache days at month 3 vs 3.3 with placebo (P<0.001).2

Patients randomized to monthly dosing had a mean baseline of 12.8 headache days of at least moderate severity per month and experienced, on average1:

5.1 fewer headache days at month 3 vs 3.3 with placebo (P<0.001).2

*Reduction in monthly average number of headache days from the Long-Term Extension study was 6.8 with monthly dosing.2

EPISODIC MIGRAINE

In episodic migraine, a reduction in monthly migraine days was demonstrated during the 12-week period (primary endpoint), with results seen as early as week 11,2

Line chart describing clinical trial data of the pivotal HALO Episodic Migraine trial from months 1 to 3 and Long-Term Extension study from months 3 to 12.

Consider limitations of Long-Term Extension study design when interpreting efficacy results.

Patients randomized to quarterly dosing had a mean baseline of 9.2 migraine days per month and experienced, on average1:

4.2 fewer migraine days at month 3 vs 3.1 with placebo (P<0.001).2

Patients randomized to monthly dosing had a mean baseline of 8.9 migraine days per month and experienced, on average1:

4.3 fewer migraine days at month 3 vs 3.1 with placebo (P<0.001).2

†Reduction in monthly average number of migraine days from the Long-Term Extension study was 5.1 with monthly dosing.2

Patients who previously participated in the clinical trials of AJOVY were recruited to complete an online survey.‡

70% of survey participants reported that they would rather choose quarterly dosing instead of monthly dosing.

When given the power to choose:

Nearly 70% of people reported that they would choose quarterly dosing instead of monthly dosing.2

DOSING ONLY 4 TIMES A YEAR

‡253 chronic and episodic migraine patients who previously participated in clinical trials were recruited to complete an online survey. Patients, blinded as to whether they received monthly or quarterly injections of AJOVY, were asked, “Would you rather take the injectable migraine medicine as 1 injection once a month or 3 injections once every 3 months?” 69% of respondents said they’d rather take the quarterly dosing option and 31% said they’d rather take the monthly dosing option.1

In clinical trials AJOVY reduced migraine days by 50% or more for some patients1

CHRONIC MIGRAINE

Secondary endpoint

≥ 50%

REDUCTION

in monthly average headache days with quarterly dosing1

37.6% vs 18.1% with placebo (P<0.001)1

Exploratory analysis

≥ 75%

REDUCTION

in monthly average headache days with quarterly dosing1

20% vs 10.4% with placebo (Exploratory analysis)2

Exploratory analysis

100%

REDUCTION

in monthly average headache days with quarterly dosing1

7.7% vs 4.2% with placebo (Exploratory analysis)2

Similar reductions seen with monthly dosing in chronic migraine patients§

§With monthly dosing, reduction in monthly average headache days of at least moderate severity: 40.8% of patients achieved a ≥50% reduction vs 18.1% with placebo (P<0.001), 20.6% achieved a ≥75% reduction vs 10.4% with placebo (exploratory analysis), and 7.5% achieved 100% reduction vs 4.2% for placebo (exploratory analysis).1,2

EPISODIC MIGRAINE

Secondary endpoint

≥ 50%

REDUCTION

in monthly average migraine days with quarterly dosing1

44.4% vs 27.9% with placebo (P<0.001)1

Exploratory analysis

≥ 75%

REDUCTION

in monthly average migraine days with quarterly dosing1

25.8% vs 15.4% with placebo (Exploratory analysis)2

Exploratory analysis

100%

REDUCTION

in monthly average migraine days with quarterly dosing1

8.5% vs 4.5% with placebo (Exploratory analysis)2

Similar reductions seen with monthly dosing in episodic migraine patients1II

‖With monthly dosing, reduction in monthly average migraine days: 47.7% of patients achieved a ≥50% reduction vs 27.9% with placebo (P<0.001), 27.1% achieved a ≥75% reduction vs 15.4% with placebo (exploratory analysis), and 10.1% achieved 100% reduction vs 4.5% for placebo (exploratory analysis).1,2

Suggestions to explore next

Continue to Half Life and antibody type page

AJOVY was also studied in patients with an inadequate response to 2 or more classes of prior preventative treatments2

 See Clinical Trial Results
Continue to AJOVY Dosing page

Only 4 injection days per year with quarterly dosing

 dosing for AJOVY
Continue to AJOVY Patient Support page

Savings Offer coupon for AJOVY

 Learn how much AJOVY may cost eligible patients